πŸ‡ΊπŸ‡Έ FDA
Patent

US 8518980

Treatment of Duchenne muscular dystrophy

granted A61KA61K31/343A61K31/404

Quick answer

US patent 8518980 (Treatment of Duchenne muscular dystrophy) held by Summit Corporation Plc expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Summit Corporation Plc
Grant date
Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/343, A61K31/404, A61K31/4184, A61K31/4192